Literature DB >> 8757305

Intracellular signaling for inducible antigen receptor-mediated Fas resistance in B cells.

L C Foote1, T J Schneider, G M Fischer, J K Wang, B Rasmussen, K A Campbell, D H Lynch, S T Ju, A Marshak-Rothstein, T L Rothstein.   

Abstract

CD40 ligand-activated B cells are sensitive targets for CD4+ Th1 effector cells that kill in a Fas-dependent fashion. Susceptibility to apoptosis is counteracted by Ag receptor binding that produces a state of resistance to Fas engagement in otherwise sensitive targets. In the present study, protection from Th1-mediated apoptosis was found to be induced by protein kinase C and calcium signals, which in combination mimicked the level of Fas resistance produced by surface Ig engagement. Signaling for Fas resistance did not alter Fas expression. Furthermore, B cells that were protected against Th1-mediated apoptosis were also resistant to apoptosis mediated by soluble, rFas ligand. Taken together, these results indicate that signaling for protection against Fas-mediated apoptosis does not depend on alteration of the interaction between B cell target and Th1 effector populations. Instead, surface IgM-derived protein kinase C and calcium signals appear to produce an intracellular change in the Fas signaling pathway that develops over a period of hours and interferes with the apoptotic process through a mechanism that depends on protein synthesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8757305

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

Review 1.  Death receptor signaling and autoimmunity.

Authors:  Richard M Siegel; Jagan Muppidi; Margaret Roberts; Melissa Porter; Zhengqi Wu
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

2.  Precursor B cells for autoantibody production in genomically Fas-intact autoimmune disease are not subject to Fas-mediated immune elimination.

Authors:  S Hirose; K Yan; M Abe; Y Jiang; Y Hamano; H Tsurui; T Shirai
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

3.  Lack of activation induced cell death in human T blasts despite CD95L up-regulation: protection from apoptosis by MEK signalling.

Authors:  L S Walker; J D McLeod; G Boulougouris; Y I Patel; C N Ellwood; N D Hall; D M Sansom
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

4.  Proteasome regulation of activation-induced T cell death.

Authors:  H Cui; K Matsui; S Omura; S L Schauer; R A Matulka; G E Sonenshein; S T Ju
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

5.  Fas apoptosis inhibitory molecule expression in B cells is regulated through IRF4 in a feed-forward mechanism.

Authors:  Hiroaki Kaku; Thomas L Rothstein
Journal:  J Immunol       Date:  2009-11-01       Impact factor: 5.422

6.  4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway.

Authors:  A C Gingras; S G Kennedy; M A O'Leary; N Sonenberg; N Hay
Journal:  Genes Dev       Date:  1998-02-15       Impact factor: 11.361

7.  Crystallization and preliminary X-ray crystallographic studies of human FAIM protein.

Authors:  Guoming Li; Linglong Qu; Geng Meng; Xiaoyun Bai; Kesheng Dai; Xiaofeng Zheng
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-07-29

8.  Fas apoptosis inhibitory molecule enhances CD40 signaling in B cells and augments the plasma cell compartment.

Authors:  Hiroaki Kaku; Thomas L Rothstein
Journal:  J Immunol       Date:  2009-07-10       Impact factor: 5.422

9.  A novel gene coding for a Fas apoptosis inhibitory molecule (FAIM) isolated from inducibly Fas-resistant B lymphocytes.

Authors:  T J Schneider; G M Fischer; T J Donohoe; T P Colarusso; T L Rothstein
Journal:  J Exp Med       Date:  1999-03-15       Impact factor: 14.307

10.  The Fas/CD95 Receptor Regulates the Death of Autoreactive B Cells and the Selection of Antigen-Specific B Cells.

Authors:  Gabor Koncz; Anne-Odile Hueber
Journal:  Front Immunol       Date:  2012-07-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.